Market research
MURA Mural Oncology plc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 35M
- P/E ratio
- Not available
- Analyst target
- 6
- Dividend yield
- Not available
- Beta
- 2.96
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- IE000LK2BOB4
- Market cap
- 35M
- P/E ratio
- Not available
- Analyst target
- 6
- Dividend yield
- Not available
- Beta
- 2.96
About
About Mural Oncology plc
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland. As of December 4, 2025, Mural Oncology plc operates as a subsidiary of XOMA Royalty Corporation.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the MURA discussion.
No comments yet
Start a focused discussion about MURA.